TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05800418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab Injection
Description: Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab Injection [Cyramza]
Description: Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
Study: NCT02963740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone Calls
Description: Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
Study: NCT02448771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Study: NCT02963740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
Study: NCT01942785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
Study: NCT04464785

Intervention type: DEVICE
Intervention: CentriMag Circulatory Support System
Description: The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
Study: NCT02396628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
Study: NCT00623701

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allerslit forte
Description: sublingual placebo preparation, daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allerslit forte
Description: Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
Study: NCT01927705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-AD Inj.
Study: NCT00539435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Insulin on cardiac disease in diabetic pts
Description: Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Study: NCT01637181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Description: EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Description: EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
Study: NCT00806156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 q14d
Description: NKTR-102 given on a q14 day schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 q21d
Description: NKTR-102 given on a q21 day schedule
Study: NCT03558477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 1
Description: YYD601 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 2
Description: YYD601 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 3
Description: YYD601 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Nexium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Nexium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Nexium
Study: NCT04393506

Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical surgery
Description: Radical surgery will be performed on the 42th-45th after initiation of inductive therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative radiotherapy/chemoradiotherapy
Description: Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
Study: NCT04700449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind 0.2mg CBP-307
Description: 0.2 mg capsule oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Placebo
Description: Placebo capsule oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label CBP-307
Description: 0.2 mg capsule oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind 0.1mg CBP-307
Description: 0.1 mg capsule oral administration
Study: NCT02334371

Intervention type: RADIATION
Group type: OTHER
Intervention: MR-PET
Description: The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
Study: NCT01513551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine (V114)
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX® 23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PREVNAR 13®
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
Study: NCT03699267

Intervention type: OTHER
Intervention: US-guided Bilateral TAP block

Intervention type: OTHER
Intervention: US-guided Bilateral TAP block
Study: NCT01267266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hydrocortisone/placebo
Description: Given orally
Study: NCT03565809

Intervention type: OTHER
Intervention: Incidence analysis
Description: Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.

Intervention type: OTHER
Intervention: Incidence analysis
Description: Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
Study: NCT03282240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD
Description: 0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed TIV-HD1
Description: 0.5 mL-dose was administered IM into the upper arm area.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational TIV-HD2
Description: 0.5 mL-dose was administered IM into the upper arm area.
Study: NCT03751059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac 0.07% Oph Susp
Description: Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
Study: NCT02845843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Lopinavir /Ritonavir and Interferon beta-1b
Description: Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
Study: NCT03242720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Ablation for Atrial Fibrillation
Description: Ablation of arrhythmia focus in the heart for atrial fibrillation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cardiac Ablation for Atrial Fibrillation
Description: Ablation of arrhythmia focus in the heart for atrial fibrillation
Study: NCT02465853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Injection Hyaluronic Acid in the experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Description: Injection 0.9% Physiological saline solution\<1.0 ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and occupational therapy
Description: rehabilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy and occupational therapy
Description: rehabilitation
Study: NCT04227704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 50 MG/ML
Description: Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 50 MG/ML
Description: Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Administration of 0.9% Sodium Chloride (N/S)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: Administration of 0.9% Sodium Chloride (N/S)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: Administration of 0.9% Sodium Chloride (N/S)
Study: NCT00231803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined CKD and CVD Prevention
Description: Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular Disease prevention
Description: Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Chronic Kidney Disease complications
Description: Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No prescribed intervention, just those that the patient's own family physician thought indicated
Study: NCT02760277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.25 mg/day/day
Description: Oral administration of 0.25 mg/kg/day daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.75 mg/day/day
Description: Oral administration of 0.75 mg/kg/day daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 mg/day/day
Description: Oral administration of 2.0 mg/kg/day daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 6.0 mg/day/day
Description: Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Study: NCT02880540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT04518605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein breakfast
Description: Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein breakfast
Description: Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein breakfast
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein breakfast
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will be asked to participate in organized exercise training 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will be asked to participate in organized exercise training 3 times per week.
Study: NCT02031549

Intervention type: OTHER
Intervention: SpermComet assay
Description: Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
Study: NCT01026493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 21 days
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 21 days
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg x 5 days
Description: 150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg x 5 days
Description: 150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Study: NCT01412762

Intervention type: BEHAVIORAL
Intervention: patient interviews
Description: The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.

Intervention type: BEHAVIORAL
Intervention: CITSAV survey
Description: Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
Study: NCT01026493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 5 days
Description: 40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 5 days
Description: 40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Study: NCT02879214

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous boost along with chemo
Description: Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
Study: NCT02597413

Intervention type: PROCEDURE
Intervention: Catheterization
Description: Women in this group will be systematically catheterized before leaving the delivery room.
Study: NCT01515839

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin Supplement intervention
Description: We recommend the following protocol:~1. 2 tablets of a high quality multivitamin BID~2. 2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3. 3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~4. Weight loss
Study: NCT01841372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second Life
Description: Second Life is an online virtual reality environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Phone Conference Call
Study: NCT00505921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 IV over 1 hour on day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen for Allogenic Stem Cell Transplantation
Description: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m2 IV twice on day -5 to -2 (total 8 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 IV on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV/day (days -6 to -4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose total body irradiation
Description: Low dose total body irradiation of 2 Gy day 0.
Study: NCT01458626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine 20mg QD
Description: paroxetine 20mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine 20mg QD
Description: paroxetine 20mg QD
Study: NCT00772837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole + Clarithromycin + Amoxycillin
Description: Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole + placebo antibiotics
Description: omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week